Arcutis Q2 2023: ZORYVE revenue $4.8M (+72% QoQ); net loss $71M

Arcutis Biotherapeutics, Inc.

2023-Q2 EPS reported -$2.46 revenue$7,971,000

Total revenues $5.2M; ZORYVE net product revenue $4.8M, up 72% sequentially.
Net loss $71.0M ($1.16 per share) vs $67.4M ($1.31) in Q2 2022.
Cash and marketable securities $269.6M as of June 30 vs $410.8M at Dec 31, 2022.
Commercial coverage expanded to >130M lives (all 3 largest PBMs) for ZORYVE.
FDA action date Dec 16, 2023 for roflumilast foam in seborrheic dermatitis; sNDA for atopic dermatitis expected late Q3/early Q4 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Arcutis Biotherapeutics, Inc. reported quarter ended June 30, 2023 results: revenue $4.8 million.

Period: quarter ended June 30, 2023
Revenue: $4.8 million
Result: reported results

Exact text from the filing

Arcutis Announces Second Quarter 2023 Financial Results and Provides Business Update • Achieved total revenues of $5.2 million in the second quarter of 2023.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Arcutis Biotherapeutics, Inc. reported quarter ended June 30, 2023 results: revenue $4.8 million.

Period: quarter ended June 30, 2023
Revenue: $4.8 million
Result: reported results

Exact text from the filing

Net product revenues for ZORYVE® (roflumilast) cream 0.3% were $4.8 million, a 72% increase compared to the first quarter of 2023, driven by nearly 40% demand growth as well as gross-to-net improvement

View on SEC.gov

Browse all earnings releases →

Arcutis Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001787306-23-000076

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.